Imugene’s Azer-Cel Data Selected For Major Haematology Meeting
IMU: $0.035 +16.67% · MC: $20M
Imugene said its azer-cel study of treatment alongside BTK inhibitors in relapsed or refractory B-cell cancers has been selected for a poster presentation at the American Society of Hematology’s annual meeting in December. The company plans to present emerging Phase 1b data; shares rose around 13% on the day, alongside the update.

Comments